An IPRP survey of the regulatory requirements for the waiver of in vivo bioequivalence studies of generic medicinal products in certain dosage forms

An IPRP survey of the regulatory requirements for the waiver of in vivo bioequivalence studies of generic medicinal products in certain dosage forms

Publication: J Pharm Pharm Sci

The requirements to waive in vivo bioequivalence studies for immediate release solid oraldosage forms based on the Biopharmaceutics Classifications System (BCS) are well known, and biowaiversafor other types of oral dosage forms based on pre-defined criteria may also be acceptable.

Neutralization of European, South African, and United States SARS-CoV-2 mutants by a human antibody and antibody domains

Neutralization of European, South African, and United States SARS-CoV-2 mutants by a human antibody and antibody domains

Publication: bioRxiv

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) transmission with several emerging variants remain uncontrolled in many countries, indicating the pandemic remains severe.

Leveraging Oral Drug Development to a Next Level: Impact of the IMI-Funded OrBiTo Project on Patient Healthcare

Leveraging Oral Drug Development to a Next Level: Impact of the IMI-Funded OrBiTo Project on Patient Healthcare

Publication: Front Med (Lausanne)
Software: GastroPlus®
Division: PBPK

A thorough understanding of the behavior of drug formulations in the human gastrointestinal (GI) tract is essential when working in the field of oral drug development in a pharmaceutical company.

Prediction of Plasma Concentrations Using In Silico Modeling and Simulation Approach: Case of Acebutolol

Prediction of Plasma Concentrations Using In Silico Modeling and Simulation Approach: Case of Acebutolol

Authors: Bokri E, Felfel H, Bahri S
Publication: Ann Pharm Fr
Software: GastroPlus®
Division: PBPK

The aim of this study was to predict the plasma concentrations of acebutolol tablets with different dissolution profiles using computer modelling and evaluating whether they are bioequivalent using simulated population studies.

Understanding Carrier Performance in Low-Dose Dry Powder Inhalation: An In Vitro–In Silico Approach

Understanding Carrier Performance in Low-Dose Dry Powder Inhalation: An In Vitro–In Silico Approach

Publication: Pharmaceutics
Software: GastroPlus®

The use of physiologically based pharmacokinetic (PBPK) models to support drug product development has become increasingly popular.

Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration

Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration

Publication: J Med Chem
Software: ADMET Predictor®

Developing in silico models to predict the brain penetration of drugs remains a challenge owing to the intricate involvement of multiple transport systems in the blood brain barrier, and the necessity to consider a...

A PK/PD model of saxagliptin: to simulate its pharmacokinetics and pharmacodynamics in healthy adults and patients with impaired hepatic function

A PK/PD model of saxagliptin: to simulate its pharmacokinetics and pharmacodynamics in healthy adults and patients with impaired hepatic function

Authors: Shi L, Miao F, Wang G, Sun W, Liu Y
Publication: Journal of Chinese Pharmaceutical Sciences
Software: GastroPlus®

In this study, we aimed to develop and evaluate a whole-body physiologically based pharmacokinetic (WB-PBPK)/pharmacodynamic (PD) model for...

On Absorption Modeling and Food Effect Prediction of Rivaroxaban, a BCS II Drug Orally Administered as an Immediate-Release Tablet

On Absorption Modeling and Food Effect Prediction of Rivaroxaban, a BCS II Drug Orally Administered as an Immediate-Release Tablet

Publication: Pharmaceutics
Software: GastroPlus®
Division: PBPK

The present work evaluates the food effect on the absorption of rivaroxaban (Riva), a BCS II drug, from the orally administered commercial immediate-release tablet (Xarelto IR) using physiologically based pharmacokinetic (PBPK)...

Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19

Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19

Publication: Mol Divers
Software: ADMET Predictor®

The presence of pharmaceutically active substances (PhACs) in aquatic ecosystems is of great concern due to their constant occurrence in different water systems and potential negative effects and ground water on the...